Whether you are a current or former user of Kombiglyze XR, there are plenty of reasons you may want to consider filing a lawsuit. These reasons include enhanced natriuretic peptide levels and the risk of heart failure, as well as over-promotion of the drug and complaints against AstraZeneca.
Increased risk of heart failure
During a recent safety review, the FDA found that Onglyza and Kombiglyze XR Lawsuit may increase the risk of heart failure. These medicines are used to treat type 2 diabetes.
The FDA conducted a safety review that included the results of two large clinical trials. The FDA also recommended that manufacturers add new warnings to the drug’s labels.
Several studies showed an increased risk of heart failure with Onglyza and Kombiglyze. Those with diabetes are already at an increased risk for heart disease. Those who have a history of heart failure are also at higher risk of heart failure hospitalization.
The FDA is urging patients who take Onglyza to talk with their health care professional about their risks for heart failure. They also recommend that patients not stop taking their medicine without talking to a doctor first.
Complaints against AstraZeneca
Hundreds of complaints against AstraZeneca over Kombiglyze XR have been filed in the US, and there are many more pending. Plaintiffs claim that the manufacturers of the drug failed to warn patients of the risk of heart failure and pancreatic cancer.
Many individuals have suffered from heart problems while taking the medication. The drug has been linked to an increased risk of congestive heart failure, myocardial infarction and pancreatic cancer. Several studies have been conducted to determine the risks of taking the drug.
The FDA has investigated the possible heart risks of the medication, and in February 2017, it ordered stronger warnings for all drugs containing the ingredient. It also requested manufacturers to demonstrate that new antidiabetic drugs do not increase the risk of cardiovascular problems.
Enhanced natriuretic peptide levels
Boosted natriuretic peptide levels are a good thing if you are a patient with heart failure. This prescription medication may be available to you if you have a government insured health plan. However, beware of the side effects.
BNP is no slouch when it comes to detecting if a patient has heart failure, and is a great metric to use when making a diagnosis. A study compared BNP levels to a number of other indicators. It also showed that elevated levels were a good indicator of future heart failure.
A study in the TIMI 16 database of patients with acute coronary syndrome analyzed BNP levels in the context of an artery blockage. It found that the BNP scalability factor was more than a third. The most intriguing part of this study is that it was performed in a high-risk group of patients.
Hundreds of lawsuits have been filed against AstraZeneca, the manufacturer of the diabetes medication Onglyza, for the link between the drug and thyroid cancer. This type of lawsuit is a form of product liability, where the plaintiff alleges that the manufacturer of the drug violated consumer protection laws. A successful plaintiff may receive compensation for pain and suffering, and possibly monetary damages.
Kombiglyze is part of a new class of diabetes drugs known as DPP-4 inhibitors. These drugs act by mimicking the hormones that are produced by the incretin glands in the gut. These hormones are known to play a key role in the production of insulin after meals.
Some studies have shown that the use of this drug can increase the risk of developing chronic pancreatitis and pancreatic cancer. The FDA is investigating these findings.
Over-promotion of the drug
KOMBIGLYZE XR is a prescription medicine made by Bristol Myers Squibb and AstraZeneca that combines the two antihyperglycemic medicines, metformin and saxagliptin. The combination is intended to lower blood sugar levels in people with type 2 diabetes. It is also designed to prevent cardiovascular complications like stroke and heart attacks.
The drug has garnered a lot of attention over the past few years, but the jury is still out on whether it really works. In fact, there have been lawsuits filed by former users, and the FDA announced that it has been linked to a higher risk of heart failure.
As the name suggests, KOMBIGLYZE XR has been used by tens of thousands of people with type 2 diabetes, but it is not clear that it is effective. The medicine is not approved for use by patients under the age of 18, and should be avoided in patients with renal impairment.